Vinod Subramaniam

Prof. Vinod Subramaniam


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Journal of Molecular Biology
Verified
Journal Article
Closed access
WHWolfgang Hoyer
Wolfgang Hoyer
TAThomas Antony
Thomas Antony
DCDmitry Cherny
Dmitry Cherny
GHGudrun Heim
Gudrun Heim
TJThomas M. Jovin
Thomas M. Jovin
VSVinod Subramaniam
Vinod Subramaniam

3 September 2010 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
IKInna Kuperstein
Inna Kuperstein
KBKerensa Broersen
Kerensa Broersen
IBIryna Benilova
Iryna Benilova
JRJef Rozenski
Jef Rozenski
WJWim Jonckheere
Wim Jonckheere
BSBart De Strooper
Bart De Strooper
The amyloid peptides Aβ40 and Aβ42 of Alzheimer's disease are thought to contribute differentially to the disease process. Although Aβ42 seems more pathogenic than Aβ40, the reason for this is not well understood. We show here that small alterations in the Aβ42:Aβ40 ratio dramatically affect the biophysical and biological properties of the Aβ mixtures reflected in their aggregation kinetics, the morphology of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo . A minor increase in the Aβ42:Aβ40 ratio stabilizes toxic oligomeric species with intermediate conformations. The initial toxic impact of these Aβ species is synaptic in nature, but this can spread into the cells leading to neuronal cell death. The fact that the relative ratio of Aβ peptides is more crucial than the absolute amounts of peptides for the induction of neurotoxic conformations has important implications for anti‐amyloid therapy. Our work also suggests the dynamic nature of the equilibrium between toxic and non‐toxic intermediates.

26 November 2004 in Biochemistry
Verified
Journal Article
Closed access
WHWolfgang Hoyer
Wolfgang Hoyer
DCDmitry Cherny
Dmitry Cherny
VSVinod Subramaniam
Vinod Subramaniam
TJThomas M. Jovin
Thomas M. Jovin

21 September 1999 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
GSGeorge Striker
George Striker
VSVinod Subramaniam
Vinod Subramaniam
CSClaus A.M. Seidel
Claus A.M. Seidel
AVAndreas Volkmer
Andreas Volkmer

29 December 2006 in Nano Letters
Verified
Journal Article
Closed access
AYAurel Ymeti
Aurel Ymeti
JGJan Greve
Jan Greve
PLPaul V Lambeck
Paul V Lambeck
TWThijs Wink
Thijs Wink
SHStephan W F M Van Hövell
Stephan W F M Van Hövell
JKJohannes S Kanger
Johannes S Kanger

22 April 2004 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CFClaudio O. Fernandez
Claudio O. Fernandez
WHWolfgang Hoyer
Wolfgang Hoyer
MZMarkus Zweckstetter
Markus Zweckstetter
EJElizabeth A Jares‐Erijman
Elizabeth A Jares‐Erijman
VSVinod Subramaniam
Vinod Subramaniam
TJThomas M. Jovin
Thomas M. Jovin
The aggregation of α‐synuclein is characteristic of Parkinson's disease (PD) and other neurodegenerative synucleinopathies. The 140‐aa protein is natively unstructured; thus, ligands binding to the monomeric form are of therapeutic interest. Biogenic polyamines promote the aggregation of α‐synuclein and may constitute endogenous agents modulating the pathogenesis of PD. We characterized the complexes of natural and synthetic polyamines with α‐synuclein by NMR and assigned the binding site to C‐terminal residues 109–140. Dissociation constants were derived from chemical shift perturbations. Greater polyamine charge (+2 → +5) correlated with increased affinity and enhancement of fibrillation, for which we propose a simple kinetic mechanism involving a dimeric nucleation center. According to the analysis, polyamines increase the extent of nucleation by ∼104 and the rate of monomer addition ∼40‐fold. Significant secondary structure is not induced in monomeric α‐synuclein by polyamines at 15°C. Instead, NMR reveals changes in a region (aa 22–93) far removed from the polyamine binding site and presumed to adopt the β‐sheet conformation characteristic of fibrillar α‐synuclein. We conclude that the C‐terminal domain acts as a regulator of α‐synuclein aggregation.